Europe Human Microbiome Market

Europe Human Microbiome Market Size (2023 to 2028)

The size of the human microbiome market in the European region is forecasted to be worth USD 878.03 million by 2028 from USD 331.88 million in 2023, growing at a CAGR of 21.48% from 2023 to 2028.

Factors such as the continued trend of self-cleaning technologies in many end-user industries, increasing prevalence of chronic lifestyle diseases and microbial dysbiosis infections, increased use of plastic and paper as packaging materials, and the growth of the senior population, which is more susceptible to microbial diseases, are expected to drive the development of the Europe human microbiome market. Human microbiomes find their use self-cleanse fabric, antimicrobial coatings for hospital infections, polycarbonate substrate, etc. On average, approximately 5.8% of patients acquired an infection across EU countries during their hospital stay in 2017-18. The percentage observed was lowest in Bulgaria, Germany, Latvia, the Netherlands, and Romania, recoding at less than 4%. In contrast, the highest infection rate was observed in Greece, Italy, Finland, and Cyprus at over 8%.

The market's growth can also be attributed to the increasing focus on developing more effective human microbiome therapies. For example, human gut microbiomes are developed in specific combinations as treatment modalities for various gastrointestinal conditions such as Irritable bowel syndrome, Gastrointestinal reflux syndrome, Crohn's disease, etc. Irritable bowel syndrome affects around 10-15% of the European population. These numbers are anticipated to increase owing to lifestyle stress, unhealthy diet, drug and alcohol abuse, and increased use of GMOs in food items. In addition, human microbiomes help study the severity of infections and develop appropriate therapies and vaccines. Factors such as infection, inflammation, diet, xenobiotics, hygiene, and altered host genetics can cause an imbalance in the gut microflora. Therefore, efforts are underway to design interventions to modulate the microbiome to improve human health. These targeted microbiome-based therapies are also driving the growth of the market. However, other factors, including extensive research and development activities and significant growth in the pharmaceutical industry, are expected to drive the market growth.

However, strict government guidelines, the high cost of microbiome therapy, lack of reimbursement policies, concerns about the effectiveness of the microbiome-based therapies, and a lack of detailed control and knowledge are likely to impact the market's growth for years to come negatively. For example, according to the International Agency for Research on Cancer, the inhalable powder of human microbiome mixture containing titanium oxide is regarded as a carcinogen because of its potential to induce lung cancer due to inhalation. This, in turn, is expected to dampen the growth of the European human microbiome market.

This research report on the European human microbiome market has been segmented and sub-segmented into the following categories.

By Disease:

• Obesity
• Diabetes
• Autoimmune Disorders
• Cancer
• Mental Disorders
• Infectious disease

By Product:

• Probiotic
• Foods
• Medical Foods
• Diagnostic Device
• Drugs
• Supplements

By Application:

• Therapeutics
• Diagnostics

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regionally, the German market is expected to dominate the European human microbiome market during the forecast period, owing to the increasing incidence rate of various gastrointestinal disorders, a significant investment for studying about human microbiome for research and development, and the increased awareness of probiotics for their role in preventive health and in balancing the gut microbiome. Furthermore, according to an article published by the Centers for Disease Control and Prevention, 2019, Clostridium difficile infection is one of the most common nosocomial infections globally, resulting in more than 50,000 deaths annually.

The United Kingdom is expected to experience significant growth in the European human microbiome market, owing to the increase in research and development activities of market players and increased healthcare awareness in the population. As a result, the probiotics market in the United Kingdom is expected to register a CAGR of 5.6%. As a result, demand for probiotics in the UK is expected to grow the fastest in Europe. This growing demand is set to grab the attention of international key players, which will provide many growth opportunities in the UK and other European regions.

KEY MARKET PLAYERS:

Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome Inc., Osel Inc., Second Genome, Kallyope, Finch Therapeutics, Concentric, Synthetic Biologics, Inc., DuPont, BiomX Ltd, MaaT Pharma, Eligo Bioscience, SNIPR Biome, Ritter Pharmaceuticals, DayTwo, Yeda Research and Development Co. Ltd., MyBiome, AOBiome, Enterome, Yakult Honsha Co., Ltd., MicroBiome Therapeutics LLC, and Metabiomics Corporate are companies playing a leading role in the European human microbiome market.